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Abstract
Background: Methicillin-resistant Staphylococcus aureus is an increasing problem in the Caribbean. We investigated
the molecular epidemiology of MRSA isolates on Cuba.
Findings: The predominant clone was of the spa type t149, followed by community-associated MRSA USA300.
Conclusions: We report the first molecular typing results of MRSA isolates from Cuba.
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Findings
In this study we aim to investigate the molecular epide-
miology of methicillin-resistant Staphylococcus aureus
(MRSA) clinical isolates from 4 major hospitals in Cuba.
MRSA is an increasing problem in the Americas and the
Caribbean including Cuba[1-4]. Although epidemiological
data on MRSA in Cuba is available, so far no molecular
typing has been performed[1,3]. Percentages of nosoco-
mial S. aureus isolates resistant to methicillin ranges
between 6% in Cuba to 85% in Peru[1]. Recently, MRSA
isolates are emerging as significant pathogens in the com-
munity [3,5]. In the USA, the most prevalent CA- MRSA
clone is USA300 (CC8, spa type t008, PVL+). In settings
with a high prevalence of MRSA, MRSA is an important
cause of nosocomial infections [6]. High MRSA prevalence
rates have major consequences for infection control poli-
cies in hospitals. Microbiological surveillance is an impor-
tant tool to evaluate this local infection control policy and
to assess which microorganisms are causative pathogens
in these settings. Surveillance per se probably results in a
decrease of nosocomial infections as is shown by the Inter-
national Nosocomial Infection Control Consortium
(INICC)[7]. INICC and the World Health Organization’s
global program of “clean care, is safer care” advocate cost-
effectiveness of microbiological surveillance in low-
resource settings. Despite the fact that device-associated
(DA-) and other healthcare-associated infection (HAI)
rates are much higher in low and middle income coun-
tries, most studies on MRSA and HAIs have been con-
ducted in high resource countries [7-9]. A prospective
cohort study in two adult intensive care units of Cuban
university hospitals showed a DA-HAI overall rate of 30.6
(95% CI 27.8-33.5) per 1000 ICU-days. DA-HAI rates for
Ventilator Associated Pneumonia (VAP), Central line-
associated bloodstream infection (CLA-BSI) and catheter-
associated urinary tract infections (CAUTI) were used to
calculate the overall DA-HAI rate. CLA-BSI rates ranged
from 1.9 to 2.3 per 1000 central line-days[10]. As Staphy-
lococcus spp. is an important pathogen of CLA-BSI’s, the
existence of MRSA in Cuba could result in increased treat-
ment failures. This could later pose an even higher burden
of HAI’s on the Cuban health care system. A system with
great emphasis on disease prevention and primary care
rather than on medical supplies and technologies [11]
During a 3 months period in 2008 all clinical isolates
suspected to be MRSA were collected prospectively at
three major Cuban hospitals and the national reference
centre for infectious diseases, the Pedro Kouri Institute
Havana, The Pediatric Hospital “William Soler” Havana,
The General Hospital “Hermanos Ameijeiras” Havana and
the General hospital “Manuel Ascunse” Camaguey. Regis-
tration of the origins of isolate cultures as well as standard
microbiological testing, including oxacillin susceptibility
testing (by CLSI) was performed in Cuba. Only clinical
relevant isolates were included. No further clinical data
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was available. The origins of isolate cultures were wounds,
bronchial/tracheal aspirations, blood, skin, abdominal drai-
nage and chest tissue biopsy in 13, 8, 7, 5, 5, 1 and 1 iso-
lates, respectively. Further molecular testing was done in
the Netherlands, including detection of Panton-Valentine
leukocidin (PVL), mecA, the Sa442 element as well as typ-
ing by and spa-typing.
Of the 68 suspected Staphylococcus spp. isolates that
were sent to the Netherlands, 40 were mecA positive and
confirmed to be MRSA. Thus routinely performed pheno-
typical identification of MRSA isolates had a high false
positive rate 41%. Spa typing identified 5 different spa-
types. In decreasing frequency we found spa-type t149
(n = 24), t008 (n = 8), t037 (n = 6), and one each of t4088
(closely related to t149) and t2029 (closely related to t037).
All eight t008 isolates but none of the other spa types
were PVL positive. Multi locus sequence typing (MLST)
was performed on t008 isolates and isolates proved to be
CC8 positive.
CA-MRSA USA300 was first described in the USA
where it has become endemic. Subsequently, this strain
has been spread to Latin America [3]. Given Cuba’s isola-
tion and the USA’s embargo on travel, we were surprised
to find that USA300 was the second most common strain
found in this study. It highlights the widespread localiza-
tion of this strain over the Americas.
Surgical-site infections (SSI) are the leading health-care-
associated infection hospital-wide in the developing world
[7]. In our study 35% of the cultures originated from
wounds obtained after surgery. This demonstrates the
importance of microbiological testing and infection con-
trol measures aiming to prevent SSI’s. Preventing MRSA
positive SSI’s is probably cost-beneficial, as the treatment
of these infections is performed with second and third line
antibiotic regimens. Those antibiotics are often difficult to
obtain in low and middle-income countries, are more
expensive and as such pressing on pre-existing limited
financial resources.
In conclusion we report the first molecular typing
results of MRSA isolates from Cuba. The predominant
clone was the spa-type 149, followed by community asso-
ciated MRSA USA300.
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